Research

Therapeutics Targeting Phospho-BRD4

BRD4 Bromodomain Inhibitors
BRD4 Bromodomain Inhibitors

The identification of BRD4 as a cancer therapeutic target through pathway discovery and development of small compound inhibitors and PROTAC-based BRD4 degraders has significantly advanced research interest in BRD4.

Our lab has identified dozens of small compound inhibitors targeting phospho-BRD4 through high-throughput compound library screening. 

We are currently refining these compound studies and hoping to develop more potent and selective isoform-specific inhibitors and/or degraders to inhibit only oncogenic but not tumor-suppressive activity of BRD4, allowing more precise targeted therapy for future cancer patient treatment.Therapeutics Targeting BRD4 Bromodomains and the N-terminal Cluster of CK2 Phosphorylation Sites (NPS)

Therapeutics Targeting BRD4 Bromodomains and the N-terminal Cluster of CK2 Phosphorylation Sites (NPS)